NCT03483324View on ClinicalTrials.gov

Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 24, 2018

Primary Completion Date

December 21, 2020

Study Completion Date

January 31, 2022

Conditions
Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia in RemissionMyelodysplastic SyndromesOther Acute Leukemias
Interventions
BIOLOGICAL

Unmanipulated Umbilical Cord Blood (UCB)

Human leukocyte antigen (HLA) matched umbilical cord blood

BIOLOGICAL

AB-110

Expanded cord blood stem cells and engineered human endothelial cells

Trial Locations (3)

10065

Memorial Sloan Kettering Cancer Center, New York

80045

University of Colorado Cancer Center University of Colorado Anschutz Medical Campus, Aurora

91010

City of Hope Comprehensive Cancer Center, Duarte

Sponsors
All Listed Sponsors
collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

lead

Angiocrine Bioscience

INDUSTRY

NCT03483324 - Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation | Biotech Hunter | Biotech Hunter